Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials

REFERENCES

1. 1.↵
   1. Brooks PM

   . The burden of musculoskeletal disease—a global perspective. Clin Rheumatol 2006;25:778–81.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Meune C,
   2. Touzé E,
   3. Trinquart L,
   4. Allanore Y

   . Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009;48:1309–13.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Watson DJ,
   2. Rhodes T,
   3. Guess HA

   . All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Sokka T,
   2. Abelson B,
   3. Pincus T

   . Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26 Suppl 51:S35–61.

   OpenUrlPubMed
5. 5.↵
   1. Meek IL,
   2. Vonkeman HE,
   3. van de Laar MA

   . Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature. BMC Musculoskelet Disord 2014;15:142.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Singh JA,
   2. Furst DE,
   3. Bharat A,
   4. Curtis JR,
   5. Kavanaugh AF,
   6. Kremer JM,
   7. et al.

   2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625–39.

   OpenUrlCrossRef
7. 7.↵
   1. Smolen JS,
   2. Landewé R,
   3. Breedveld FC,
   4. Buch M,
   5. Burmester G,
   6. Dougados M,
   7. et al.

   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Tymms K,
   2. Zochling J,
   3. Scott J,
   4. Bird P,
   5. Burnet S,
   6. de Jager J,
   7. et al.

   Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res 2014;66:190–6.

   OpenUrlCrossRef
9. 9.↵
   1. Carson CW,
   2. Cannon GW,
   3. Egger MJ,
   4. Ward JR,
   5. Clegg DO

   . Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987;16:186–95.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Sakai F,
    2. Noma S,
    3. Kurihara Y,
    4. Yamada H,
    5. Azuma A,
    6. Kudoh S,
    7. et al.

    Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005;15:173–9.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Kamata Y,
    2. Nara H,
    3. Kamimura T,
    4. Haneda K,
    5. Iwamoto M,
    6. Masuyama J,
    7. et al.

    Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004;43:1201–4.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Suissa S,
    2. Hudson M,
    3. Ernst P

    . Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Roubille C,
    2. Haraoui B

    . Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014;43:613–26.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Bongartz T,
    2. Nannini C,
    3. Medina-Velasquez YF,
    4. Achenbach SJ,
    5. Crowson CS,
    6. Ryu JH,
    7. et al.

    Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583–91.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Doran MF,
    2. Crowson CS,
    3. Pond GR,
    4. O’Fallon WM,
    5. Gabriel SE

    . Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Raj R,
    2. Nugent K

    . Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis 2013;30:167–76.

    OpenUrlPubMed
17. 17.↵
    1. Conway R,
    2. Low C,
    3. Coughlan RJ,
    4. O’Donnell MJ,
    5. Carey JJ

    . Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 2014;66:803–12.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Cochrane Informatics & Knowledge Management Department

    . RevMan, version 5.1. [Internet. Accessed February 4, 2016.] Available from: tech.cochrane.org/revman
19. 19.↵
    1. Higgins JP,
    2. Green S

    , eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0. [Internet. Accessed February 2, 2016.] Available from: www.cochrane-handbook.org
20. 20.↵
    1. Chen L,
    2. Qi H,
    3. Jiang D,
    4. Wang R,
    5. Chen A,
    6. Yan Z,
    7. et al.

    The new use of an ancient remedy: a double-blinded randomized study on the treatment of rheumatoid arthritis. Am J Chin Med 2013;41:263–80.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Jaimes-Hernández J,
    2. Meléndez-Mercado CI,
    3. Mendoza-Fuentes A,
    4. Aranda-Pereira P,
    5. Castañeda-Hernández G

    . Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial. Reumatol Clin 2012;8:243–9.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Ishaq M,
    2. Muhammad JS,
    3. Hameed K,
    4. Mirza AI

    . Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. Mod Rheumatol 2011;21:375–80.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Kremer JM,
    2. Genovese MC,
    3. Cannon GW,
    4. Caldwell JR,
    5. Cush JJ,
    6. Furst DE,
    7. et al.

    Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726–33.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Cohen S,
    2. Cannon GW,
    3. Schiff M,
    4. Weaver A,
    5. Fox R,
    6. Olsen N,
    7. et al.

    Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984–92.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Emery P,
    2. Breedveld FC,
    3. Lemmel EM,
    4. Kaltwasser JP,
    5. Dawes PT,
    6. Gömör B,
    7. et al.

    A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655–65.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Smolen JS,
    2. Kalden JR,
    3. Scott DL,
    4. Rozman B,
    5. Kvien TK,
    6. Larsen A,
    7. et al.

    Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259–66.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Mladenovic V,
    2. Domljan Z,
    3. Rozman B,
    4. Jajic I,
    5. Mihajlovic D,
    6. Dordevic J,
    7. et al.

    Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595–603.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Conway R,
    2. Low C,
    3. Coughlan RJ,
    4. O’Donnell MJ,
    5. Carey JJ

    . Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 2015;350:h1269.

    OpenUrlAbstract/FREE Full Text